PMID- 23617089
OWN - NLM
STAT- MEDLINE
DCOM- 20130620
LR  - 20131121
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 91
IP  - 3
DP  - 2013 Mar
TI  - Efficacy and tolerability of fixed-combination acne treatment in adolescents.
PG  - 152-9
AB  - Acne is common among adolescents and can be difficult to manage. Providing an 
      effective treatment method that offers an early onset of action and a favorable 
      tolerability profile may lead to improved adherence, increased satisfaction, and 
      improved clinical outcomes in this patient population. A post hoc analysis was 
      conducted of 1755 adolescents (age range, 12 to < 18 years) with moderate to 
      severe acne who had been enrolled in 2 double-blind, multicenter studies and were 
      randomized to receive either clindamycin phosphate (CP) 1.2%-benzoyl peroxide 
      (BPO) 2.5% gel, CP 1.2%, BPO 2.5%, or vehicle once daily for 12 weeks. 
      Significantly superior reductions in inflammatory, noninflammatory, and total 
      lesion counts were observed in the CP 1.2%-BPO 2.5% gel group versus the other 3 
      groups (P < or = .002 for all week 12 pairwise comparisons). At week 12, 
      treatment success with CP 1.2%-BPO 2.5% gel was statistically superior to CP 1.2% 
      (P = .004), BPO 2.5% (P = .031), and vehicle (P < .001). Participants observed 
      improvement with CP 1.2%-BPO 2.5% gel treatment as early as week 2, with 31.4% of 
      participants reporting their skin was clear, almost clear, or showed marked 
      improvement. Clindamycin phosphate 1.2%-BPO 2.5% gel was associated with a low 
      incidence of treatment-related adverse events (AEs) and a favorable cutaneous 
      tolerability profile. Clindamycin phosphate 1.2%-BPO 2.5% gel is an effective, 
      safe, and well-tolerated treatment in adolescents with moderate to severe acne. 
      The once-daily regimen, early signs of improvement, favorable cutaneous 
      tolerability profile, and participant satisfaction may lead to increased 
      adherence and improved clinical outcomes.
FAU - Gold, Linda Stein
AU  - Gold LS
AD  - Department of Dermatology, Henry Ford Medical Center, Detroit, MI 48202, USA. 
      lstein1@hfhs.org
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Gels)
RN  - 0 (clindamycin phosphate benzoyl peroxide combination)
RN  - 3U02EL437C (Clindamycin)
RN  - W9WZN9A0GM (Benzoyl Peroxide)
SB  - IM
MH  - Acne Vulgaris/*drug therapy/pathology
MH  - Administration, Cutaneous
MH  - Adolescent
MH  - Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use
MH  - Benzoyl Peroxide/administration & dosage/adverse effects/*therapeutic use
MH  - Child
MH  - Clindamycin/administration & dosage/adverse effects/*therapeutic use
MH  - Dermatologic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Gels
MH  - Humans
MH  - Male
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2013/04/27 06:00
MHDA- 2013/06/21 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/27 06:00 [entrez]
PHST- 2013/04/27 06:00 [pubmed]
PHST- 2013/06/21 06:00 [medline]
PST - ppublish
SO  - Cutis. 2013 Mar;91(3):152-9.